⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025

Figure S1 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

Kunling Chen Huolun Feng Yujie Zhang Jingyuan Pei Yuyan Xu Xiangxu Wei Zhuohao Chen Zhoubin Feng Lei Cai Yong Li Liang Zhao Mingxin Pan

View at Publisher

Ask AI

Bookmark

Share

Key Points

CCL16 negatively regulates tumor vasculature, leading to improved tumor treatment responses.
The mechanism involves macrophage interactions via ICAM-1, indicating a vital role in liver cancer.
Findings suggest that enhancing CCL16 levels may be a promising strategy for liver cancer immunotherapy.
The study underscores the importance of targeting tumor vasculature in hepatocellular carcinoma treatment.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Analysis reveals CCL16 enhances immunotherapy efficacy by regulating macrophage and tumor vasculature interactions.

Abstract

Liver-specific secretion of CCL16 negatively regulates tumor vasculature.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21b16 https://doi.org/10.1158/0008-5472.30254944

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
2Figure S6 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
3Figure S7 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
4Figure S8 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
5Figure S9 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025

Figure S5 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
Table S1 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
Data from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025